A recent study detected Dab2 promoter hypermethylation in 11% (6 out of 54) of primary breast tumours, whereas overall 74% (67 out of 91) of breast tumours analyzed displayed decreased Dab2 protein expression, leading the authors to suggest that Dab2 promoter hypermethylation is an infrequent cause for loss of Dab2 expression in breast cancer (Bagadi et al, 2006). The gene discussed is DAB2; the disease is breast carcinoma.